Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
420 Leser
Artikel bewerten:
(2)

Meticulous Market Research Pvt. Ltd: Pharmaceutical Contract Development and Manufacturing Market Worth $226.35 Billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research

Finanznachrichten News

REDDING, Calif., June 15, 2022 /PRNewswire/ -- According to a new market research report, "Pharmaceutical Contract Development & Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Global Forecast to 2029," published by Meticulous Research, the pharmaceutical contract development and manufacturing market is expected to grow at a CAGR of 7.5% from 2022 to reach $226.35 billion by 2029.

Meticulous_Research_Logo_1

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5171

Pharmaceutical contract development and manufacturing organization offers various services based on a contract to small or large pharmaceutical companies. These services include active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, drug development & drug discovery services, and biologics manufacturing services.

The growth of the pharmaceutical contract development and manufacturing market is attributed to the complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination toward the use of cutting-edge technologies, patent expiration of pharmaceuticals, increasing investments in pharmaceutical R&D, the rising demand for generic medicines & biologics, and the outbreak of the COVID-19 pandemic.

In addition, the growing demand for cell and gene therapies and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs) markets is expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market. However, the lack of skilled professionals and the introduction of serialization are some of the challenges to the growth of this market.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5171

The global pharmaceutical contract development and manufacturing market is segmented on the basis of service {manufacturing [API, FDF (parenteral, tablet, capsule, oral liquid)], drug development, biologics manufacturing, packaging}, end user [large pharma, generic]. The study also evaluates industry competitors and analyzes their market share at global and regional levels.

Based on service, the global pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. In 2022, the pharmaceutical manufacturing services segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. The large market share of this segment is attributed to the growing need to reduce manufacturing costs in the pharmaceutical industry, the increasing requirement for high-quality bulk manufacturing, and the growing demand for generic drugs. However, the biologics manufacturing services segment is expected to grow at the highest CAGR during the forecast period.

Based on end user, the pharmaceutical contract development and manufacturing market is segmented into large pharmaceutical companies, small & mid-size pharmaceutical companies, and generic pharmaceutical companies. In 2022, the large pharmaceutical companies segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. The large market share of this segment is attributed to the increasing demand from businesses worldwide, the increasing need for state-of-the-art processes and production technologies, and the continued efforts of pharmaceutical companies to reduce production costs.

Based on geography, in 2022, North America is expected to account for the largest share of the pharmaceutical contract development and manufacturing market, followed by Europe and Asia-Pacific. The large share of this region is mainly attributed to the growing demand for generic drugs and biologics, increasing consolidation of CDMOs, the rising demand for biosimilars due to patent expiry, and increasing expenditures on outsourcing. Furthermore, the contract manufacturing market in North America is highly competitive due to organizations' emphasis on pharmaceutical and biotechnology research. However, Asia-Pacific is slated to register the highest CAGR during the forecast period.

Quick Buy - Pharmaceutical Contract Development & Manufacturing Market - Global Opportunity Analysis And Industry Forecast (2022-2029): https://www.meticulousresearch.com/Checkout/67156803

The report includes an extensive assessment of the service portfolio, geographic analysis, and key strategic developments in the industry's leading market participants over the past four years (2019-2022). The report also covers the list of manufacturing facilities of the major players and market share analysis for the top 19 players in the market.

The pharmaceutical contract development and manufacturing market has witnessed several partnerships, collaborations, & agreements; acquisitions; and expansions in recent years. For instance, in April 2022, Cambrex Corporation (U.S.) invested USD 50 million to expand its large-scale active pharmaceutical ingredient (API) manufacturing capabilities in Charles City, Iowa, U.S. This expansion will increase the capacity of Cambrex's API facility by 30%. In December 2021, Samsung Biologics extended its agreement with AstraZeneca plc (U.K.) to produce drug substances and products. In January 2021, Thermo Fisher Scientific, Inc. (U.S.) acquired the European viral vector manufacturing business Groupe Novasep SAS (France) to provide manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers.

Some of the key players operating in this market are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GmbH (Germany), Piramal Enterprises Limited (India), Almac Group (U.K.), Cambrex Corporation (U.S.), Samsung Biologics Co., Ltd (South Korea), Siegfried Holding AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), Aenova Group (Germany), Jubilant Pharmova Limited (India), Curia Global, Inc. (U.S.), C.H. Boehringer Sohn AG & Co. KG (Germany), Fareva SA (Luxembourg), Fabbrica Italiana Sintetici S.p.A. (Italy), WuXi Biologics (Cayman) Inc. (China), and Aurobindo Pharma Ltd. (India).

Browse in-depth TOC on "Pharmaceutical Contract Development & Manufacturing Market- Global Opportunity Analysis And Industry Forecast (2022-2029)"
click here: https://www.meticulousresearch.com/product/pharmaceutical-contract-development-and-manufacturing-market-5171

Scope of the Report:

Pharmaceutical Contract Development and Manufacturing Market, by Service

  • Pharmaceutical Manufacturing Services
    • API Manufacturing Services
    • FDF Manufacturing Services
      • Parenteral/Injectable Manufacturing Services
      • Tablet Manufacturing Services
      • Capsule Manufacturing Services
      • Oral Liquid Manufacturing Services
      • Other Formulations Manufacturing Services
  • Drug Development Services
  • Biologics Manufacturing Services
    • API Manufacturing Services
    • API Manufacturing Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

  • Large Pharmaceutical Companies
  • Small and Med-Size Pharmaceutical Companies
  • Generic Pharmaceutical Companies

Pharmaceutical Contract Development and Manufacturing Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5171

Related Reports:

Contract Research Organizations (CRO) Market by Services (Clinical Research [Phase II, Phase III], Pre-Clinical [Pharmacokinetics, Toxicology], Laboratory Services, and others), Therapeutic Area (Oncology, Immunology), End User (Pharma and Biotech, Medical Device), and Geography - Forecast to 2027

https://www.meticulousresearch.com/product/CRO-market-5129

Pharmaceutical Processing and Packaging Equipment Market by Mode of Delivery (Oral, Parenteral, Topical), Secondary Packaging (Cartoning, Labelling, Serialization), and End-of-Line Packaging (Palletizing, Case Packaging) - Global Forecasts to 2028

https://www.meticulousresearch.com/product/pharmaceutical-processing-and-packaging-equipment-market-5021

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Content Source: https://www.meticulousresearch.com/pressrelease/391/pharmaceutical-contract-development-and-manufacturing-market-2029

Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg

© 2022 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.